Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.
Identifieur interne : 000039 ( Main/Exploration ); précédent : 000038; suivant : 000040Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.
Auteurs : Elizabeth G. Graham-Gurysh [États-Unis] ; Ananya B. Murthy [États-Unis] ; Kathryn M. Moore [États-Unis] ; Shawn D. Hingtgen [États-Unis] ; Eric M. Bachelder [États-Unis] ; Kristy M. Ainslie [États-Unis]Source :
- Journal of controlled release : official journal of the Controlled Release Society [ 1873-4995 ] ; 2020.
Abstract
Glioblastoma (GBM) is a highly aggressive and heterogeneous form of brain cancer. Genotypic and phenotypic heterogeneity drives drug resistance and tumor recurrence. Combination chemotherapy could overcome drug resistance; however, GBM's location behind the blood-brain barrier severely limits chemotherapeutic options. Interstitial therapy, delivery of chemotherapy locally to the tumor site, via a biodegradable polymer implant can overcome the blood-brain barrier and increase the range of drugs available for therapy. Ideal drug candidates for interstitial therapy are those that are potent against GBM and work in combination with both standard-of-care therapy and new precision medicine targets. Herein we evaluated paclitaxel for interstitial therapy, investigating the effect of combination with both temozolomide, a clinical standard-of-care chemotherapy for GBM, and everolimus, a mammalian target of rapamycin (mTOR) inhibitor that modulates aberrant signaling present in >80% of GBM patients. Tested against a panel of GBM cell lines in vitro, paclitaxel was found to be effective at nanomolar concentrations, complement therapy with temozolomide, and synergize strongly with everolimus. The strong synergism seen with paclitaxel and everolimus was then explored in vivo. Paclitaxel and everolimus were separately formulated into fibrous scaffolds composed of acetalated dextran, a biodegradable polymer with tunable degradation rates, for implantation in the brain. Acetalated dextran degradation rates were tailored to attain matching release kinetics (~3% per day) of both paclitaxel and everolimus to maintain a fixed combination ratio of the two drugs. Combination interstitial therapy of both paclitaxel and everolimus significantly reduced GBM growth and improved progression free survival in two clinically relevant orthotopic models of GBM resection and recurrence. This work illustrates the advantages of synchronized interstitial therapy of paclitaxel and everolimus for post-surgical tumor control of GBM.
DOI: 10.1016/j.jconrel.2020.04.028
PubMed: 32335153
PubMed Central: PMC7453575
Affiliations:
- États-Unis
- Caroline du Nord
- Chapel Hill (Caroline du Nord)
- Université de Caroline du Nord à Chapel Hill
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.</title><author><name sortKey="Graham Gurysh, Elizabeth G" sort="Graham Gurysh, Elizabeth G" uniqKey="Graham Gurysh E" first="Elizabeth G" last="Graham-Gurysh">Elizabeth G. Graham-Gurysh</name><affiliation wicri:level="4"><nlm:affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill</wicri:regionArea><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author><name sortKey="Murthy, Ananya B" sort="Murthy, Ananya B" uniqKey="Murthy A" first="Ananya B" last="Murthy">Ananya B. Murthy</name><affiliation wicri:level="4"><nlm:affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill</wicri:regionArea><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author><name sortKey="Moore, Kathryn M" sort="Moore, Kathryn M" uniqKey="Moore K" first="Kathryn M" last="Moore">Kathryn M. Moore</name><affiliation wicri:level="1"><nlm:affiliation>Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University</wicri:regionArea><wicri:noRegion>University of North Carolina at Chapel Hill and North Carolina State University</wicri:noRegion></affiliation></author><author><name sortKey="Hingtgen, Shawn D" sort="Hingtgen, Shawn D" uniqKey="Hingtgen S" first="Shawn D" last="Hingtgen">Shawn D. Hingtgen</name><affiliation wicri:level="4"><nlm:affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill</wicri:regionArea><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author><name sortKey="Bachelder, Eric M" sort="Bachelder, Eric M" uniqKey="Bachelder E" first="Eric M" last="Bachelder">Eric M. Bachelder</name><affiliation wicri:level="4"><nlm:affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill</wicri:regionArea><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author><name sortKey="Ainslie, Kristy M" sort="Ainslie, Kristy M" uniqKey="Ainslie K" first="Kristy M" last="Ainslie">Kristy M. Ainslie</name><affiliation wicri:level="4"><nlm:affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA; Department of Microbiology and Immunology, UNC School of Medicine, University of North Carolina, Chapel Hill, NC, USA. Electronic address: ainsliek@email.unc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA; Department of Microbiology and Immunology, UNC School of Medicine, University of North Carolina, Chapel Hill, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region><settlement type="city">Chapel Hill (Caroline du Nord)</settlement></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32335153</idno><idno type="pmid">32335153</idno><idno type="doi">10.1016/j.jconrel.2020.04.028</idno><idno type="pmc">PMC7453575</idno><idno type="wicri:Area/Main/Corpus">000087</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000087</idno><idno type="wicri:Area/Main/Curation">000087</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000087</idno><idno type="wicri:Area/Main/Exploration">000087</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.</title><author><name sortKey="Graham Gurysh, Elizabeth G" sort="Graham Gurysh, Elizabeth G" uniqKey="Graham Gurysh E" first="Elizabeth G" last="Graham-Gurysh">Elizabeth G. Graham-Gurysh</name><affiliation wicri:level="4"><nlm:affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill</wicri:regionArea><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author><name sortKey="Murthy, Ananya B" sort="Murthy, Ananya B" uniqKey="Murthy A" first="Ananya B" last="Murthy">Ananya B. Murthy</name><affiliation wicri:level="4"><nlm:affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill</wicri:regionArea><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author><name sortKey="Moore, Kathryn M" sort="Moore, Kathryn M" uniqKey="Moore K" first="Kathryn M" last="Moore">Kathryn M. Moore</name><affiliation wicri:level="1"><nlm:affiliation>Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University</wicri:regionArea><wicri:noRegion>University of North Carolina at Chapel Hill and North Carolina State University</wicri:noRegion></affiliation></author><author><name sortKey="Hingtgen, Shawn D" sort="Hingtgen, Shawn D" uniqKey="Hingtgen S" first="Shawn D" last="Hingtgen">Shawn D. Hingtgen</name><affiliation wicri:level="4"><nlm:affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill</wicri:regionArea><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author><name sortKey="Bachelder, Eric M" sort="Bachelder, Eric M" uniqKey="Bachelder E" first="Eric M" last="Bachelder">Eric M. Bachelder</name><affiliation wicri:level="4"><nlm:affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill</wicri:regionArea><placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement><region type="state">Caroline du Nord</region></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author><author><name sortKey="Ainslie, Kristy M" sort="Ainslie, Kristy M" uniqKey="Ainslie K" first="Kristy M" last="Ainslie">Kristy M. Ainslie</name><affiliation wicri:level="4"><nlm:affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA; Department of Microbiology and Immunology, UNC School of Medicine, University of North Carolina, Chapel Hill, NC, USA. Electronic address: ainsliek@email.unc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA; Department of Microbiology and Immunology, UNC School of Medicine, University of North Carolina, Chapel Hill, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region><settlement type="city">Chapel Hill (Caroline du Nord)</settlement></placeName><orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName></affiliation></author></analytic><series><title level="j">Journal of controlled release : official journal of the Controlled Release Society</title><idno type="eISSN">1873-4995</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Glioblastoma (GBM) is a highly aggressive and heterogeneous form of brain cancer. Genotypic and phenotypic heterogeneity drives drug resistance and tumor recurrence. Combination chemotherapy could overcome drug resistance; however, GBM's location behind the blood-brain barrier severely limits chemotherapeutic options. Interstitial therapy, delivery of chemotherapy locally to the tumor site, via a biodegradable polymer implant can overcome the blood-brain barrier and increase the range of drugs available for therapy. Ideal drug candidates for interstitial therapy are those that are potent against GBM and work in combination with both standard-of-care therapy and new precision medicine targets. Herein we evaluated paclitaxel for interstitial therapy, investigating the effect of combination with both temozolomide, a clinical standard-of-care chemotherapy for GBM, and everolimus, a mammalian target of rapamycin (mTOR) inhibitor that modulates aberrant signaling present in >80% of GBM patients. Tested against a panel of GBM cell lines in vitro, paclitaxel was found to be effective at nanomolar concentrations, complement therapy with temozolomide, and synergize strongly with everolimus. The strong synergism seen with paclitaxel and everolimus was then explored in vivo. Paclitaxel and everolimus were separately formulated into fibrous scaffolds composed of acetalated dextran, a biodegradable polymer with tunable degradation rates, for implantation in the brain. Acetalated dextran degradation rates were tailored to attain matching release kinetics (~3% per day) of both paclitaxel and everolimus to maintain a fixed combination ratio of the two drugs. Combination interstitial therapy of both paclitaxel and everolimus significantly reduced GBM growth and improved progression free survival in two clinically relevant orthotopic models of GBM resection and recurrence. This work illustrates the advantages of synchronized interstitial therapy of paclitaxel and everolimus for post-surgical tumor control of GBM.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">32335153</PMID><DateRevised><Year>2020</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-4995</ISSN><JournalIssue CitedMedium="Internet"><Volume>323</Volume><PubDate><Year>2020</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of controlled release : official journal of the Controlled Release Society</Title><ISOAbbreviation>J Control Release</ISOAbbreviation></Journal><ArticleTitle>Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.</ArticleTitle><Pagination><MedlinePgn>282-292</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0168-3659(20)30242-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jconrel.2020.04.028</ELocationID><Abstract><AbstractText>Glioblastoma (GBM) is a highly aggressive and heterogeneous form of brain cancer. Genotypic and phenotypic heterogeneity drives drug resistance and tumor recurrence. Combination chemotherapy could overcome drug resistance; however, GBM's location behind the blood-brain barrier severely limits chemotherapeutic options. Interstitial therapy, delivery of chemotherapy locally to the tumor site, via a biodegradable polymer implant can overcome the blood-brain barrier and increase the range of drugs available for therapy. Ideal drug candidates for interstitial therapy are those that are potent against GBM and work in combination with both standard-of-care therapy and new precision medicine targets. Herein we evaluated paclitaxel for interstitial therapy, investigating the effect of combination with both temozolomide, a clinical standard-of-care chemotherapy for GBM, and everolimus, a mammalian target of rapamycin (mTOR) inhibitor that modulates aberrant signaling present in >80% of GBM patients. Tested against a panel of GBM cell lines in vitro, paclitaxel was found to be effective at nanomolar concentrations, complement therapy with temozolomide, and synergize strongly with everolimus. The strong synergism seen with paclitaxel and everolimus was then explored in vivo. Paclitaxel and everolimus were separately formulated into fibrous scaffolds composed of acetalated dextran, a biodegradable polymer with tunable degradation rates, for implantation in the brain. Acetalated dextran degradation rates were tailored to attain matching release kinetics (~3% per day) of both paclitaxel and everolimus to maintain a fixed combination ratio of the two drugs. Combination interstitial therapy of both paclitaxel and everolimus significantly reduced GBM growth and improved progression free survival in two clinically relevant orthotopic models of GBM resection and recurrence. This work illustrates the advantages of synchronized interstitial therapy of paclitaxel and everolimus for post-surgical tumor control of GBM.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Graham-Gurysh</LastName><ForeName>Elizabeth G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murthy</LastName><ForeName>Ananya B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Kathryn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hingtgen</LastName><ForeName>Shawn D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachelder</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ainslie</LastName><ForeName>Kristy M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA; Department of Microbiology and Immunology, UNC School of Medicine, University of North Carolina, Chapel Hill, NC, USA. Electronic address: ainsliek@email.unc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 CA225199</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097507</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Control Release</MedlineTA><NlmUniqueID>8607908</NlmUniqueID><ISSNLinking>0168-3659</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acetalated dextran (Ace-DEX)</Keyword><Keyword MajorTopicYN="N">Everolimus</Keyword><Keyword MajorTopicYN="N">LN-229</Keyword><Keyword MajorTopicYN="N">Paclitaxel</Keyword><Keyword MajorTopicYN="N">U87-MG</Keyword><Keyword MajorTopicYN="N">mTOR</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>07</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32335153</ArticleId><ArticleId IdType="pii">S0168-3659(20)30242-X</ArticleId><ArticleId IdType="doi">10.1016/j.jconrel.2020.04.028</ArticleId><ArticleId IdType="pmc">PMC7453575</ArticleId><ArticleId IdType="mid">NIHMS1589457</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cancer Res. 1994 Jul 1;54(13):3506-10</Citation><ArticleIdList><ArticleId IdType="pubmed">7912167</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2004 Dec;190(2):478-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15530886</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12479-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9356475</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80</Citation><ArticleIdList><ArticleId IdType="pubmed">8134351</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 1990 Jan;150(1):173-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2404479</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Apr 13;10(4):e0123721</Citation><ArticleIdList><ArticleId IdType="pubmed">25867026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2001 Feb 15;61(4):1527-32</Citation><ArticleIdList><ArticleId IdType="pubmed">11245461</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Oncol. 2016 Dec;18(12):1622-1633</Citation><ArticleIdList><ArticleId IdType="pubmed">27298311</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">19321415</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancers (Basel). 2019 May 29;11(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">31146485</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2005 Jun 20;105(1-2):43-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15908033</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2009 Aug 4;137(3):203-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19376172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Chemother Pharmacol. 1994;34(6):465-71</Citation><ArticleIdList><ArticleId IdType="pubmed">7923556</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2008 Jan 22;5(1):e8</Citation><ArticleIdList><ArticleId IdType="pubmed">18215105</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2009 Jun;30(18):3189-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19285718</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Oncol. 2015;4(2):91-104</Citation><ArticleIdList><ArticleId IdType="pubmed">25768333</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2015 Feb 26;372(9):793-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25635347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Mater Res B Appl Biomater. 2008 Jan;84(1):138-46</Citation><ArticleIdList><ArticleId IdType="pubmed">17474078</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Clin Cancer Res. 2012 Sep 20;31:78</Citation><ArticleIdList><ArticleId IdType="pubmed">22992374</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Appl Mater Interfaces. 2020 Apr 29;12(17):19345-19356</Citation><ArticleIdList><ArticleId IdType="pubmed">32252517</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Surg Oncol. 2016 Aug 24;14(1):225</Citation><ArticleIdList><ArticleId IdType="pubmed">27557526</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosurgery. 2010 Mar;66(3):530-7; discussion 537</Citation><ArticleIdList><ArticleId IdType="pubmed">20173548</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2013 Sep 17;109(6):1482-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23963141</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 1992;22(3):613-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1346533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2018 Mar 5;15(3):1309-1318</Citation><ArticleIdList><ArticleId IdType="pubmed">29342360</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2008 May;29(13):1989-2006</Citation><ArticleIdList><ArticleId IdType="pubmed">18281090</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 2006 Aug;23(8):1817-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16841195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Ther. 2004 Dec;3(12):1605-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15634654</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1978 Jun;41(6):2431-7</Citation><ArticleIdList><ArticleId IdType="pubmed">274993</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurooncol. 2002 Oct;60(1):53-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12416546</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2018 Jan 28;270:1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">29170142</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2010 Jul;31(19):5199-207</Citation><ArticleIdList><ArticleId IdType="pubmed">20350766</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Cell. 2003 Nov;4(5):343-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14667501</ArticleId></ArticleIdList></Reference><Reference><Citation>Australas Radiol. 2000 Feb;44(1):84-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10761264</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Oncol Rep. 2009 Jan;11(1):53-61</Citation><ArticleIdList><ArticleId IdType="pubmed">19080742</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2007 Feb;21(2):333-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17136116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Ther. 2012 Oct;11(10):2233-42</Citation><ArticleIdList><ArticleId IdType="pubmed">22896668</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 2011 Apr 15;317(7):1049-59</Citation><ArticleIdList><ArticleId IdType="pubmed">21199649</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S78-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25722936</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2018 Sep 4;15(9):3672-3681</Citation><ArticleIdList><ArticleId IdType="pubmed">29863881</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymers (Basel). 2011 Sep 1;3(3):1377-1397</Citation><ArticleIdList><ArticleId IdType="pubmed">22577513</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2004 Dec 15;122(2):131-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15542136</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2264-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16609043</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1985 Sep;35(9):1274-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3839573</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmuir. 2013 Jun 25;29(25):7957-65</Citation><ArticleIdList><ArticleId IdType="pubmed">23725054</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17933-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24114272</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 2009 Oct;26(10):2289-302</Citation><ArticleIdList><ArticleId IdType="pubmed">19639394</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Chem Soc. 2008 Aug 13;130(32):10494-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18630909</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomaterials. 2008 Jul;29(20):2996-3003</Citation><ArticleIdList><ArticleId IdType="pubmed">18423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2004 Oct 15;10(20):7031-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15501983</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2019 Sep 10;309:72-81</Citation><ArticleIdList><ArticleId IdType="pubmed">31306678</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther. 2014 Jul;22(7):1310-1319</Citation><ArticleIdList><ArticleId IdType="pubmed">24569835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1994 Apr 15;54(8):2207-12</Citation><ArticleIdList><ArticleId IdType="pubmed">7909720</ArticleId></ArticleIdList></Reference><Reference><Citation>Anticancer Drugs. 2011 Jan;22(1):58-78</Citation><ArticleIdList><ArticleId IdType="pubmed">20890178</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Oncol. 2013 Nov;15(11):1502-17</Citation><ArticleIdList><ArticleId IdType="pubmed">23897632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2005 Aug 10;23(23):5294-304</Citation><ArticleIdList><ArticleId IdType="pubmed">15998902</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurooncol. 2002 Oct;60(1):37-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12416544</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2012 Sep;17(17-18):1044-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22652342</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2003 Aug 15;9(9):3441-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12960135</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Oncol. 1999 Apr;1(2):101-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11550305</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1998 Feb 15;58(4):672-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9485020</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2015 Aug;152:63-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25944528</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2018 Jan;144(2):139-151</Citation><ArticleIdList><ArticleId IdType="pubmed">29164620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1994 Feb 1;54(3):649-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8306326</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosurg. 1992 Apr;76(4):640-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1545259</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 2006 Sep;58(3):621-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16968952</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Oct 23;455(7216):1061-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18772890</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):530-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19147017</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2012 Jul 15;431(1-2):101-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22548844</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Pharm Sci. 2015 Sep-Oct;77(5):599-604</Citation><ArticleIdList><ArticleId IdType="pubmed">26798176</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Chemother Pharmacol. 1995;37(1-2):173-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7497589</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2009 Jan 27;100(2):315-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19127256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2015 Jul;16(7):816-29</Citation><ArticleIdList><ArticleId IdType="pubmed">26092818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1995 Apr 22;345(8956):1008-12</Citation><ArticleIdList><ArticleId IdType="pubmed">7723496</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2019 Feb 10;295:93-101</Citation><ArticleIdList><ArticleId IdType="pubmed">30605703</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Nanomedicine. 2013;8:2465-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23885173</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Appl Mater Interfaces. 2012 Aug;4(8):4149-55</Citation><ArticleIdList><ArticleId IdType="pubmed">22833690</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cancer. 2006 May;42(7):934-47</Citation><ArticleIdList><ArticleId IdType="pubmed">16540312</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Pathol. 1999 Jul;9(3):469-79</Citation><ArticleIdList><ArticleId IdType="pubmed">10416987</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurooncol. 2013 Feb;111(3):229-36</Citation><ArticleIdList><ArticleId IdType="pubmed">23224713</ArticleId></ArticleIdList></Reference><Reference><Citation>J Drug Target. 2014 Aug;22(7):669-77</Citation><ArticleIdList><ArticleId IdType="pubmed">24964052</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2001 Jul 6;74(1-3):63-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11489483</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiat Oncol. 2013 Mar 19;8:65</Citation><ArticleIdList><ArticleId IdType="pubmed">23510353</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Chemother Pharmacol. 2008 Jul;62(2):305-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17912526</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Cancer Res. 2009 Sep 1;15(17):5389-95</Citation><ArticleIdList><ArticleId IdType="pubmed">19706800</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Nord</li></region><settlement><li>Chapel Hill (Caroline du Nord)</li></settlement><orgName><li>Université de Caroline du Nord à Chapel Hill</li></orgName></list><tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Graham Gurysh, Elizabeth G" sort="Graham Gurysh, Elizabeth G" uniqKey="Graham Gurysh E" first="Elizabeth G" last="Graham-Gurysh">Elizabeth G. Graham-Gurysh</name></region><name sortKey="Ainslie, Kristy M" sort="Ainslie, Kristy M" uniqKey="Ainslie K" first="Kristy M" last="Ainslie">Kristy M. Ainslie</name><name sortKey="Bachelder, Eric M" sort="Bachelder, Eric M" uniqKey="Bachelder E" first="Eric M" last="Bachelder">Eric M. Bachelder</name><name sortKey="Hingtgen, Shawn D" sort="Hingtgen, Shawn D" uniqKey="Hingtgen S" first="Shawn D" last="Hingtgen">Shawn D. Hingtgen</name><name sortKey="Moore, Kathryn M" sort="Moore, Kathryn M" uniqKey="Moore K" first="Kathryn M" last="Moore">Kathryn M. Moore</name><name sortKey="Murthy, Ananya B" sort="Murthy, Ananya B" uniqKey="Murthy A" first="Ananya B" last="Murthy">Ananya B. Murthy</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000039 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000039 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32335153
|texte= Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32335153" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |